Vaccine based on Phage Lysis Products
New Model of Vaccine Development Using Bacteriophages
Tech Area / Field
3 Approved without Funding
Georgian Academy of Sciences / Institute of Bacteriophage, Microbiology and Virology, Georgia, Tbilisi
- Walter Reed Army Institute of Research / Walter Reed Army Medical Center, USA, Washington DC\nCentre National de la Recherche Scientifique, Laboratoire de Microbiologie et Genetique Moleculaire, France, Toulouse
Project summaryThe worldwide spread of multi-drug resistant bacterial strains is becoming an ever-increasing problem resulting in increased morbidity and mortality in affected patients. This necessitates either developing new antibiotic therapeutics or alternatives to antibiotics. The improvement of existing therapeutic means or construction of new antibacterial therapeutics has become an urgent task. One possible way to solve this problem is trough the use of bacteriophages which are very specific and have directed activity towards a given pathogen.
G. Eliava Institute of Bacteriophages, Microbiology and Virology produce several different types of therapeutic and prophylactic phage preparations. Phage treatment is a part of standard healthcare protocols in Georgia, as pre-clinical and clinical investigations have been performed to determine the efficacy of phage application. One of the interesting studies performed by the Eliava Institute’s scientists is the determination of antigenic and immunogenic properties of phage lysates. It was determined that phage lysates are non-toxic and immunization with phage lysates does not cause adverse reactions. Phage treatment acts in two ways, first the phage attacks the specific pathogen and neutralizes it through lysis, and second, the resultant cell lysate acts as an immune modulator. The phage-lysates that result from repeated introduction of phages, even in small amounts, result in increasing titers of specific antibodies which behave in a dose response fashion similar to traditional vaccines.
The aim of the project is to develop and test vaccines using bacteriophages. Phage lysates with the same antigenic and immunogenic properties as vaccine based on whole bacterial cells, but with reduced toxicity could be used as a potential vaccine for prophylaxis of various infectious bacterial diseases which continue to be problematic. The relatively rapid accumulation of antibodies after immunization with phage lysates indicates the potential for successful application as a vaccine.
The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.
ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.